【券商聚焦】海通国际首予巨子生物“优于大市”评级 目标价43.6港元

金吾财讯
Jan 15

(原标题:【券商聚焦】海通国际首予巨子生物(02367)“优于大市”评级 目标价43.6港元)金吾财讯|海通国际发布研报指,巨子生物(02367.HK)作为重组胶原蛋白行业领军企业,首次覆盖给予"优于大市"评级,目标价43.6港元,较现价有22%上行空间。核心逻辑基于三点:技术优势上,公司重组胶原蛋白技术具备安全性高、功效精准及生产可持续性;产品矩阵上,可复美和可丽金两大核心品牌贡献超95%收入,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10